TMDX Soars 2.56% on $230M Volume Surge, Jumps to 456th in Daily Liquidity as Institutional Interest Revives

. 9, . equity markets. The move reflects renewed institutional interest in the organ preservation technology provider following strategic updates in its product pipeline.

Analysts highlighted recent operational milestones as potential catalysts, including expanded partnerships with transplant centers and regulatory progress on next-generation device approvals. .

For a rigorous backtest of the “top-500-by-volume, 1-day hold” strategy, key parameters require confirmation: the universe defaults to NYSE, NASDAQ, and NYSE Arca-listed stocks; ; , , and sale at close; ; and portfolio construction defaults to equal weighting unless altered. , . Finalize parameters to initiate the pipeline.